Pancreatic Ductal Adenocarcinoma (PDAC) (U.S.), November 2022
The MarketVue®: Pancreatic Ductal Adenocarcinoma (PDAC) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
Methodology:
Research for the MarketVue®: Pancreatic Ductal Adenocarcinoma report is supported by 7 qualitative interviews with key opinion leaders, a quantitative survey with 23 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
- Novartis
- Pancreatic Cancer Action Network
- Panbela Therapeutics
- BioLineRx
- Astellas Pharma
- TME Pharma
- Merck Sharp & Dohme
- SynerGene Therapeutics
- Ability Pharma
- AstraZeneca
- ERYTECH
- Cornerstone Pharmaceuticals
- Eli Lilly
- Pharmacyclics
- Halozyme Therapeutics
- Sumitomo Pharma
- FibroGen
Key drugs mentioned:
- Capecitabine
- FOLFIRINOX
- Gemcitabine
- Cisplatin
- Olaparib (Lynparza)
- Larotrectinib (Vitrakvi)
- Entrectinib (Rozlytrek)
- Pembrolizumab (Keytruda)
- Pamrevlumab
- Canakinumab (Ilaris)
- Spartalizumab
- SM-88
- Ivospemin
- Motixafortide
- Zolbetuximab
- Olaptesed pegol
- SGT-53
- ABTL0812
- Selumetinib (Koselugo)
- Durvalumab (Imfinzi)
- Paclitaxel (Abraxane)
- Eryaspase
- Devimistat
- Pegilodecakin
- Ibrutinib (Imbruvica)
- PEGPH20
- Napabucasin
1. DISEASE OVERVIEW
An aggressive, lethal cancer beginning in the ducts of the pancreas
Figure 1.1. Signs and symptoms of PDAC
Table 1.1. Risk factors associated with PDAC
PDAC is a lethal cancer with limited treatments but many potentially actionable targets
Table 1.2. Staging of disease in PDAC
Table 1.3. Five-year survival rates for pancreatic cancer
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Table 2.1. Incident populations of PDAC in the US, EU4 and UK
Drug-treated PDAC patients
Table 2.2. Drug-eligible and drug-treated PDAC patients by stage
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Oncologist-reported PDAC patient segmentation
Diagnostic journey of PDAC patients – timely diagnosis is challenging due to the nature of the symptoms
Treatment flows for resectable and borderline resectable patients
Table 3.1. Surgery-eligible PDAC patient segments
Treatment of resectable and borderline resectable PDAC
Figure 3.2. Neoadjuvant therapy use prior to surgery in surgery-eligible PDAC patients
Figure 3.3. Adjuvant therapy in patients who have undergone resection
Physician insights on drug treatment in surgery-eligible patients
Treatment of locally advanced and metastatic patients
Table 3.2. Unresectable PDAC patient segments
Treatment of metastatic patients
Figure 3.4. Percentage of oncologists who prescribe Olaparib to BRCA+ patients as a maintenance tx
FOLFIRNIOX and gemcitabine-based therapies are the backbone of PDAC treatment
Figure 3.5. Oncologist-reported current treatment share for locally advanced and metastatic patients: 1st-line setting
Figure 3.6. Oncologist-reported current treatment share for locally advanced and metastatic patients: 2nd-line setting
Identification of druggable targets guides treatment decisions in unresectable patients
Table 3.3. Genetic and somatic testing of PDAC patients
Figure 3.7. Oncologist-reported percentage of PDAC patients tested for germline and somatic mutations
Key treatment dynamics that shape disease management and drug use in PDAC
Table 3.4. Must-know PDAC treatment dynamics for now and the future
PDAC market evolution
Figure 3.8. Important dynamics of PDAC market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in PDAC
Figure 4.2. Medical Oncologist unmet needs in PDAC
Unmet needs – Physician perspectives
Clinical outcomes that impact prescribing habits – Physician perspectives
Figure 4.3. Importance of clinical outcomes on prescribing habits in 1st and 2nd line mPDAC
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Percentage of oncologists rating target as “promising” for PDAC
Physician commentary on emerging therapy targets
Late-stage clinical development for metastatic PDAC
Table 5.1. Comparison of selected late-stage trials in metastatic PDAC
Early-stage clinical development for metastatic PDAC
Table 5.2. Selected ongoing Phase 2 clinical trials
Early-stage clinical development for metastatic PDAC (continued)
Table 5.2. Selected ongoing Phase 2 clinical trials (continued)
Novel therapy trial failure in PDAC and a new approach to trial design
Table 5.3. Focus on the Phase 3 CanStem111P study of napabucasin
6. VALUE & ACCESS
Overview
Table 6.1. Current therapy pricing, US 2022
Figure 6.1. Reimbursement and Access considerations for emerging therapies in PDAC
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
Appendix: List of abbreviations used in PDAC report
Appendix: List of abbreviations used in PDAC report (continued)
What is the difference between purchasing a published report and requesting a new report?
Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.
How does REACH produce new primary market research reports in 15 business days?
By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.
Who writes REACH reports?
Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.
Does REACH cover both rare and non-rare diseases?
REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.
Can I meet with the team to discuss the report?
Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.
Published Report
New Report
Undecided about purchasing this report?
Reach out to learn more about report bundle discounts